Barclays Boosts AnaptysBio (NASDAQ:ANAB) Price Target to $79.00

AnaptysBio (NASDAQ:ANAB) had its price objective increased by investment analysts at Barclays from $78.00 to $79.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price objective points to a potential upside of 37.92% from the company’s previous close.

Other analysts also recently issued research reports about the stock. Wedbush reaffirmed an “outperform” rating and set a $50.00 price target on shares of AnaptysBio in a report on Monday, November 24th. Stifel Nicolaus dropped their target price on shares of AnaptysBio from $80.00 to $56.00 and set a “buy” rating on the stock in a report on Thursday, December 11th. Wall Street Zen lowered shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. UBS Group initiated coverage on AnaptysBio in a research note on Wednesday, January 7th. They issued a “buy” rating and a $70.00 price target on the stock. Finally, Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a report on Thursday, December 18th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $71.89.

AnaptysBio Trading Down 5.4%

ANAB stock opened at $57.28 on Wednesday. The stock has a market capitalization of $1.65 billion, a PE ratio of -110.15 and a beta of 0.32. AnaptysBio has a 12-month low of $15.32 and a 12-month high of $63.47. The stock’s 50 day simple moving average is $50.17 and its 200 day simple moving average is $38.78.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, March 9th. The biotechnology company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.69. The firm had revenue of $108.25 million during the quarter, compared to analysts’ expectations of $87.09 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%. On average, research analysts predict that AnaptysBio will post -6.08 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has approved a share buyback program on Friday, November 21st that authorizes the company to repurchase $100.00 million in outstanding shares. This repurchase authorization authorizes the biotechnology company to repurchase up to 9.6% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at AnaptysBio

In other news, insider Paul F. Lizzul sold 3,650 shares of the firm’s stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $163,191.50. Following the transaction, the insider owned 42,088 shares of the company’s stock, valued at $1,881,754.48. This trade represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric J. Loumeau sold 10,000 shares of AnaptysBio stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $54.00, for a total value of $540,000.00. Following the transaction, the insider directly owned 12,835 shares in the company, valued at approximately $693,090. The trade was a 43.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 156,280 shares of company stock valued at $7,254,939 in the last ninety days. 33.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

Hedge funds have recently modified their holdings of the company. Los Angeles Capital Management LLC increased its position in shares of AnaptysBio by 1.5% during the 4th quarter. Los Angeles Capital Management LLC now owns 15,101 shares of the biotechnology company’s stock valued at $732,000 after purchasing an additional 225 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in AnaptysBio by 24.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,345 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 263 shares during the last quarter. Larson Financial Group LLC grew its holdings in AnaptysBio by 21.2% during the 4th quarter. Larson Financial Group LLC now owns 1,624 shares of the biotechnology company’s stock valued at $79,000 after purchasing an additional 284 shares during the last quarter. Susquehanna Portfolio Strategies LLC raised its position in AnaptysBio by 1.4% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 35,948 shares of the biotechnology company’s stock worth $1,743,000 after purchasing an additional 500 shares during the period. Finally, Smartleaf Asset Management LLC lifted its stake in AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 821 shares during the last quarter.

Key AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $85 and reiterated a Buy rating, signaling substantial upside vs. current levels. Stifel Nicolaus price-target raise
• Positive Sentiment: Barclays raised its target to $79 and moved to an Overweight rating, another institutional endorsement that supports upside expectations. Barclays price-target raise
• Positive Sentiment: H.C. Wainwright boosted its target to $66 and kept a Buy rating; the firm’s analyst also published a long‑range FY2030 EPS projection (~$7.67), which is far above current consensus and implies strong optionality from AnaptysBio’s assets. H.C. Wainwright price-target raise HC Wainwright FY2030 note
• Neutral Sentiment: AnaptysBio announced a spin‑off of its biopharma portfolio — a strategic move that can unlock value long term but often creates short‑term uncertainty until details (timing, tax treatment, assets) are disclosed. Spin-off announcement
• Neutral Sentiment: Short‑interest reports show a reported “large increase” but list zero shares and NaN changes — data appears inconsistent and likely not a meaningful signal. (Treat short‑interest data as noisy/uncertain until clarified.)
• Negative Sentiment: Despite positive analyst action, intraday selling and higher-than-average volume suggest profit‑taking or rotation away from a stock that recently traded near its 1‑year high; that technical flow can drive near‑term downside even with favorable analyst commentary.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.